Cardio Diagnostics Holdings Inc (CDIO)vsNovartis AG ADR (NVS)
CDIO
Cardio Diagnostics Holdings Inc
$1.96
-7.11%
HEALTHCARE · Cap: $4.59M
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 381767774% more annual revenue ($56.58B vs $14,820). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
CDIO
Avoid23
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.2%
Fair Value
$2.41
Current Price
$1.96
$0.45 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : CDIO
The strongest argument for CDIO centers on Price/Book, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CDIO
The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
CDIO profiles as a value stock while NVS is a declining play — different risk/reward profiles.
CDIO carries more volatility with a beta of 2.26 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. CDIO offers better value entry with a 45.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cardio Diagnostics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology firm dedicated to transforming cardiovascular health through advanced diagnostic solutions. By utilizing state-of-the-art technologies, CDIO empowers healthcare providers with essential tools for the precise assessment and management of cardiovascular diseases, significantly improving patient outcomes. The company’s strong focus on personalized medicine positions it for robust growth and makes it an attractive prospect for institutional investors looking to capitalize on the advancements in the rapidly evolving healthcare landscape.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?